The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis

Stark, Mitchell S., Klein, Kerenaftali, Weide, Benjamin, Haydu, Lauren E., Pflugfelder, Annette, Tang, Yue Hang, Palmer, Jane M., Whiteman, David C., Scolyer, Richard A., Mann, Graham J., Thompson, John F., Long, Georgina V., Barbour, Andrew P., Soyer, H. Peter, Garbe, Claus, Herington, Adrian, Pollock, Pamela M. and Hayward, Nicholas K. (2015) The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis. EBioMedicine, 2 7: 671-680. doi:10.1016/j.ebiom.2015.05.011

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ362505_OA.pdf Accepted Manuscript (open access) application/pdf 1.01MB 0

Author Stark, Mitchell S.
Klein, Kerenaftali
Weide, Benjamin
Haydu, Lauren E.
Pflugfelder, Annette
Tang, Yue Hang
Palmer, Jane M.
Whiteman, David C.
Scolyer, Richard A.
Mann, Graham J.
Thompson, John F.
Long, Georgina V.
Barbour, Andrew P.
Soyer, H. Peter
Garbe, Claus
Herington, Adrian
Pollock, Pamela M.
Hayward, Nicholas K.
Title The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis
Journal name EBioMedicine   Check publisher's open access policy
ISSN 2352-3964
Publication date 2015-04-07
Year available 2015
Sub-type Article (original research)
DOI 10.1016/j.ebiom.2015.05.011
Open Access Status DOI
Volume 2
Issue 7
Start page 671
End page 680
Total pages 10
Place of publication Amsterdam, The Netherlands
Publisher Elsevier
Language eng
Abstract The overall 5-year survival for melanoma is 91%. However, if distant metastasis occurs (stage IV), cure rates are <15%. Hence, melanoma detection in earlier stages (stages I-III) maximises the chances of patient survival. We measured the expression of a panel of 17 microRNAs (miRNAs) (MELmiR-17) in melanoma tissues (stage III; n=76 and IV; n= 10) and serum samples (collected from controls with no melanoma, n= 130; and patients with melanoma (stages I/II, n = 86; III, n = 50; and IV, n = 119)) obtained from biobanks in Australia and Germany. In melanoma tissues, members of the 'MELmiR-17' panel were found to be predictors of stage, recurrence, and survival. Additionally, in a minimally-invasive blood test, a seven-miRNA panel (MELmiR-7) detected the presence of melanoma (relative to controls) with high sensitivity (93%) and specificity (>= 82%) when = 4 miRNAs were expressed. Moreover, the 'MELmiR-7' panel characterised overall survival of melanoma patients better than both serum LDH and S100B (delta log likelihood=11, p < 0.001). This panel was found to be superior to currently used serological markers for melanoma progression, recurrence, and survival; and would be ideally suited to monitor tumour progression in patients diagnosed with early metastatic disease (stages IIIa-c/IV M1a-b) to detect relapse following surgical or adjuvant treatment. (C) 2015 The Authors. Published by Elsevier B. V.
Keyword Biomarker
Diagnostic
Melanoma
MicroRNA
MiRNA
Prognostic
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2016 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 11 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 12 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 09 Jun 2015, 10:31:18 EST by System User on behalf of School of Medicine